Watson Pharmaceuticals, Inc. | Investors |
Links shared publicly online about this topic.
- 421total visits
Watson Pharmaceuticals, Inc. | Investors |
View full resource at ir.watson.com
Tags: Pharma, Watson Pharmaceuticals
Most Recently Shared on March 22, 2011 at 2:21 pm By:
Exclusive: Watson close to $7 billion Actavis drug deal: sources | Reuters
reuters.com — “LONDON/FRANKFURT (Reuters) - Watson Pharmaceuticals Inc is close to buying Swiss-based Actavis for around $7 billion, marking the latest deal between generics companies racing to achieve” View full resource at reuters.com
Most Recently Shared on March 21, 2012 at 4:54 pm By:
Reuters: Watson close to $7 billion Actavis drug deal: sources. http://t.co/jvFdkGL5
Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda | BioPortfolio.com
bioportfolio.com — “From BioPortfolio: Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today annou...” View full resource at bioportfolio.com
Most Recently Shared on March 21, 2012 at 10:32 am By:
BioPortfolio News Astex Pharmaceuticals Announces March 27th Analyst and Investor Day Agenda: ... http://t.co/SN3w7V9v BioPortfolio News
Abbott Sues Watson Over Niaspan Cholesterol Drug Patents - Bloomberg
bloomberg.com — “Abbott Laboratories sued Watson Pharmaceuticals Inc. in Wilmington, Delaware, federal court for allegedly infringing two patents for its Niaspan cholesterol drug.” View full resource at bloomberg.com
Most Recently Shared on March 19, 2012 at 7:43 pm By:
Abbott Sues Watson Over Niaspan Cholesterol Drug Patents: Abbott Laboratories sued Watson Pharmaceuticals Inc. (... http://t.co/Pc1ysln0
Abbott Sues Watson Over Niaspan Cholesterol Drug Patents - Bloomberg
bloomberg.com — “Abbott Laboratories sued Watson Pharmaceuticals Inc. in Wilmington, Delaware, federal court for allegedly infringing two patents for its Niaspan cholesterol drug.” View full resource at bloomberg.com
Most Recently Shared on March 19, 2012 at 5:39 pm By:
Watson files FDA app for generic Niaspan; Abbott sues for patent infringement http://t.co/0qHieXI1 $ABT $WPI
Abbott files suit against Watson over generic NIASPAN
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Niacin Extended-release Tablets, 500 mg and 1000 mg. Watson's ANDA products are generic versions of Abbott Laboratories' NIASPAN.” View full resource at news-medical.net
Most Recently Shared on March 19, 2012 at 2:01 pm By:
Abbott files suit against Watson over generic NIASPAN: Watson Pharmaceuticals, Inc. today confirmed that its sub... http://t.co/pk3MiGAR
Mylan drops out of Rottapharm talks: sources - Yahoo! News
news.yahoo.com — “From Yahoo! News: (Reuters) - Generics drug maker Mylan has pulled out of talks to buy a stake in Italian pharmaceuticals firm Rottapharm, two people familiar with the situation said, posing another setback to the arduous sales process that has been dragging on since the middle of last year. The Rovati family had been looking to find an investor among rival pharma groups such as Mylan, Forest Laboratories and Watson Pharmaceuticals, after it failed to sell a minority stake to private equity hous” View full resource at news.yahoo.com
Most Recently Shared on March 15, 2012 at 7:29 pm By:
HealthTrendster Health Executive
Mylan drops out of Rottapharm talks: sources - (Reuters) - Generics drug maker Mylan has pulled out of talks to buy ... http://t.co/7Uwf9HX0
Watson Confirms BYSTOLIC Patent Challenge - Drugs.com MedNews
drugs.com — “- Paragraph IV Litigation Underway - Watson Pharmaceuticals, Inc. (NYSE WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviate” View full resource at drugs.com
Most Recently Shared on March 14, 2012 at 11:03 pm By:
Drugs and Devices OW OW Health
Watson Confirms BYSTOLIC Patent Challenge: - Paragraph IV Litigation Underway - PARSIPPANY, N.J., March ... http://t.co/SxeRjCzc #drug
EntreMed announces $10 million in financing from strategic accredited investors
news-medical.net — “EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has secured $10 million in financing with strategic accredited investors, including IDG-Accel China Growth Fund II L.P., Emerging Technology Partners, LLC, and Dr. Tak W. Mak, Director of The Campbell Family Institute for Cancer Research.” View full resource at news-medical.net
Most Recently Shared on January 23, 2012 at 4:12 pm By:
EntreMed announces $10 million in financing from strategic accredited investors: EntreMed, Inc., a clinical-stag... http://t.co/uMGFf2zC
FDA approves topical gel for OAB - - ModernMedicine
modernmedicine.com — “Watson Pharmaceuticals, Inc., and Antares Pharma, Inc., recently announced the FDA approval of Antares? topical oxybutynin gel 3% for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.” View full resource at modernmedicine.com
Most Recently Shared on December 22, 2011 at 9:21 pm By:
FDA approves topical gel for OAB: Watson Pharmaceuticals, Inc., and Antares Pharma, Inc., recently announced the... http://t.co/7YPCEac9
Prostate Cancer Drugs Aren’t Tied to Heart Attacks, Study Says - Businessweek
businessweek.com — “Prostate cancer drugs from AstraZeneca Plc, Watson Pharmaceuticals Inc. and others don’t increase the risk of heart attacks in men with no history of the disease, a study said, contradicting earlier reports.” View full resource at businessweek.com
Most Recently Shared on December 9, 2011 at 12:04 am By:
john clay mchugh Doctor, Surgeon, Urologist, and Physician
Prostate Cancer Drugs Aren’t Tied to Heart Attacks, Study Says: Prostate cancer drugs from AstraZeneca Plc, Wats... http://t.co/ZP0m17OW
Watson receives FDA approval for generic Kadian ANDA
news-medical.net — “Watson Pharmaceuticals, Inc. today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian.” View full resource at news-medical.net
Most Recently Shared on November 11, 2011 at 5:17 am By:
Medicare News: Watson receives FDA approval for generic Kadian ANDA: Watson Pharmaceuticals, Inc. today announce... http://t.co/bq3BVrMo
Novartis files suit against Watson over generic Exelon
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr.” View full resource at news-medical.net
Most Recently Shared on November 11, 2011 at 5:17 am By:
Parkinson's Disease: Novartis files suit against Watson over generic Exelon: Watson Pharmaceuticals, Inc. today ... http://t.co/ldd6pUdi
3 biotech stocks battle the ‘Dendreon Effect’ - Biotech Stocks - MarketWatch
marketwatch.com — “Dendreon Corp.’s tepid sales report has not only chilled trading in the company’s once-hot stock but has also managed to frost investors in three other biotechs: Savient Pharmaceuticals, Human Genome Sciences and InterMune Inc.” View full resource at marketwatch.com
Most Recently Shared on August 19, 2011 at 12:02 pm By:
Thanks to the "Dendreon Effect," investors expect new drug launches to fall short, analysts say. http://t.co/ZJXYtu7?
Yaupon Therapeutics, Inc. Secures $14.4 Million in Series D Financing | EON: Enhanced Online News
eon.businesswire.com — “Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that it has raised $14.4 million through a Series D priv” View full resource at eon.businesswire.com
Most Recently Shared on August 11, 2011 at 12:49 pm By:
John Carroll Health Communicator
Yaupon gets $14.4M Series D from Burrill, Vivo Ventures and Palo Alto Investors. NDA on a gel for mycosis fungoides. http://bit.ly/rqMLSJ
Watson Pharmaceuticals, Inc. | Investors | RSS Content
ir.watson.com — “Watson Pharmaceuticals, Inc. | Investors | RSS Content” View full resource at ir.watson.com
Most Recently Shared on August 10, 2011 at 1:05 pm By:
eyeonfda Pharma and Health Lawyer
Watson's Rosuvastatin Zinc Tablets Receive Tentative FDA Approval - http://ow.ly/5ZEmi
Advertisement
